Resource Availability
@ American Psychiatric Association. All rights reserved. This course material was originally created for SMI Adviser, and is now utilized with permission for the APAF SMI Learning Resource Center. The content in this course material is still current and relevant, yet, please be aware that some external resources and links may no longer be active or available.
Description
Clozapine is a medication that exhibits unique efficacy and effective for those with serious mental illness. However, the risks of using clozapine, the monitoring required for its use, issues facing prescribers who may wish to employ it, and a variety of administrative burdens have all proved to be barriers to its more widespread use. This presentation will discuss the barriers to the use of clozapine and recommendations of a national workgroup seeking to overcome these barriers.
Format
Recorded webinar, non-interactive, self-paced distance learning activity with post-test.
This presentation was recorded on April 25, 2019.
Learning Objectives
Discuss the utility of clozapine in the treatment of serious mental disorders
List barriers to the use of clozapine and discuss collaborative strategies to increase access and improve its utilization
Explain new guidelines and requirements for clozapine monitoring in the US including the impact and recognition of Benign Ethnic Neutropenia
Target Audience
Psychiatrist, Physician (non-psychiatrist), Physician Assistant, Nurse Practitioner, Nurse, Pharmacist,
Instructional Level
Advanced
Estimated Time to Complete
Estimated Duration: 1.0 hour
Program Start Date: January 21, 2026
Program End Date: January 21, 2029
Certificate of Participation
After completing the evaluation, participants will have the opportunity to download a certificate of participation. No continuing education credits are provided for this activity.
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME's Standards for Integrity and Independence in Accredited Medical Education. Any individuals in a position to control the content of a CME activity - including faculty, planners, reviewers, or others - are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty
- Deanna Kelly, PharmD, BCPP, University of Maryland, School of Medicine. Disclosure: Consultant- HLS Therapeutics, Alkermes, Lundbeck, Saladax.
- Raymond Love, PharmD, BCPP, FASHP, University of Maryland, School of Pharmacy. Disclosure: Consultant- Maryland Medicaid Pharmacy Program; Grant/Research- National Institutes of Health, Maryland Department of Health; Honoraria - American Psychiatric Association, Nevada Psychiatric Association, American Pharmacists Association, and the National Alliance of State Pharmacy Associations.
Program Planners
- John Torous, MD, Beth Israel Deaconess Medical Center. Dr. Torous has no relevant financial relationships to disclose. (Reviewed on 4/19/22)
- Teri Brister, PhD, LPC, National Alliance on Mental Illness. Dr. Brister has no relevant financial relationships to disclose. (Reviewed on 4/19/22)
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.
Technical Requirements
This internet-based CME activity is best experienced using any of the following:
The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
Internet Explorer 11+
This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
Internet Connection: 1 Mbps or higher
Minimum Requirements:
Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content
For assistance: Contact for questions about this activity |
Contact for technical assistance